Inquiry Concluded
The South African Competition Commission has concluded its investigation into Johnson & Johnson (J&J) and its local subsidiary, Janssen Pharmaceuticals, over allegations of excessive pricing of the antiretroviral drug Prezista.
Background
The inquiry was launched in 2018 after allegations that J&J was charging excessive prices for Prezista, which is used to treat HIV/AIDS. The Commission found that J&J’s pricing was excessive compared to other similar drugs available in South Africa.
Settlement Reached
In response to the inquiry, J&J has agreed to reduce the price of Prezista by 33%. The company has also withdrawn its patent for the drug, which will make it easier for generic manufacturers to produce and sell more affordable versions.
Impact on Patients
The price reduction and patent withdrawal are expected to have a significant impact on the lives of people living with HIV/AIDS in South Africa. The lower price will make it more affordable for patients to access the medication they need.
Conclusion
The Competition Commission’s investigation has resulted in a positive outcome for people living with HIV/AIDS in South Africa. The price reduction and patent withdrawal will make Prezista more accessible and affordable for those who need it.
Key Points
Allegations of Excessive Pricing
- The inquiry was launched in 2018 over allegations that J&J was charging excessive prices for Prezista.
Price Reduction and Patent Withdrawal
- J&J agreed to reduce the price of Prezista by 33%.
- The company has also withdrawn its patent for the drug, making it easier for generic manufacturers to produce and sell more affordable versions.
Impact on Patients
- The lower price will make it more affordable for patients to access the medication they need.
Conclusion
- The Competition Commission’s investigation has resulted in a positive outcome for people living with HIV/AIDS in South Africa.
Kind regards
E. Thompson
